Regulatory writing for oncology
Rapid accrual, frequent DSURs, dose-optimisation pressure, and interim-analysis-heavy CSRs. Asthra keeps the documentation aligned with how oncology development actually moves.
Oncology development compresses more regulatory writing into less time than any other therapeutic area. DSURs cycle faster. CSRs carry more interim analyses. Dose optimisation is a first-class regulatory expectation, not an afterthought. Companion diagnostics co-develop alongside the therapy. Asthra drafts the regulated output against this pace, keeping citations honest and reuse tight where it belongs.
Regulatory pressure points in oncology
Where Asthra changes the shape of the work
Annual DSURs through development, then PSURs post-approval
Active oncology programs produce a DSUR every year through development and switch to periodic reporting post-approval. Asthra carries forward prior-period content where the evidence is unchanged, and flags what needs a rewrite — so each cycle is a delta, not a restart.
Interim analyses complicate the CSR narrative
Many oncology CSRs summarise interim analyses with futility or efficacy boundaries, group sequential designs, and alpha-spending corrections. Asthra cites the SAP rationale alongside the TFL outputs, so the final CSR narrative matches the statistical plan it was tested against.
Dose optimisation is a regulatory expectation
FDA Project Optimus has moved dose-optimisation reporting from a nice-to-have to a compliance requirement. Asthra pulls dose-exploration data from the protocol and interim analyses into a coherent dose-rationale narrative for the CSR and the briefing documents that precede it.
PFS, OS, and response-rate interpretation
Progression-free survival, overall survival, objective response rates — each has a specific interpretive convention, RECIST or iRECIST-linked, with confidence intervals and censoring rules. Asthra keeps the narrative interpretation tied to the TFL that produced the numbers.
Targeted-therapy safety reporting
Class-specific toxicities (cytokine release, cardiotoxicity for HER2-targeted, pneumonitis for checkpoint inhibitors, specific teratogenicity for some targeted therapies) have standing capture and reporting conventions. Asthra keeps those conventions stable across PSUR / DSUR cycles.
Documents Asthra drafts for this area
The regulated documents you produce most often
CSR (ICH E3)
Full CSR first draft with interim-analysis handling, dose-rationale narrative, and response-rate / PFS / OS interpretation aligned to RECIST conventions.
Learn more →DSUR / PSUR / PBRER
Annual DSURs during development, periodic reports post-approval. Carries forward prior content where evidence is unchanged and flags genuine deltas.
Learn more →CMC (eCTD Module 3)
Module 3 consolidation for small molecules, antibodies, and conjugates — with process-validation narrative and stability summaries.
Learn more →Regulatory context we keep in mind
Not a substitute for your regulatory strategy — just the background Asthra is aware of
FDA Project Optimus
Dose-optimisation expectations for oncology programs. Narrative must show that the chosen dose was based on rigorous exploration, not convenience.
ICH E9 and ICH E9 (R1) — Statistical Principles
Governs CSR statistical narrative, including handling of estimands, intercurrent events, and sensitivity analyses. Asthra cites SAP provisions next to results.
RECIST / iRECIST
Response assessment conventions. Asthra aligns narrative interpretation with the RECIST version used in the TFL.
ICH E14 — QT assessment
Relevant for targeted therapies with cardiotoxicity signals. Asthra keeps ECG/QT narrative tied to the underlying per-subject data.
Oncology regulatory writing is built for speed and precision at the same time. Asthra is designed to keep both, across the full development-to-periodic-reporting arc — so writers can spend their hours on interpretation, not on restitching narratives they wrote six months ago.
See Asthra on a oncology document
Bring a real source file — protocol, PSUR, CER, or Module 3 — and we'll run Asthra against it in a live demo.
Last updated: 16 April 2026